Short Interest in Avalon GloboCare Corp. (NASDAQ:ALBT) Decreases By 63.6%

Avalon GloboCare Corp. (NASDAQ:ALBT) was the target of a significant decline in short interest in January. As of January 31st, there was short interest totalling 7,200 shares, a decline of 63.6% from the January 15th total of 19,800 shares. Based on an average trading volume of 841,400 shares, the short-interest ratio is currently 0.0 days. Approximately 1.7% of the company’s stock are short sold.

Avalon GloboCare Price Performance

NASDAQ:ALBT opened at $3.54 on Thursday. Avalon GloboCare has a one year low of $2.11 and a one year high of $21.60. The company’s 50-day simple moving average is $3.60 and its 200 day simple moving average is $3.62. The firm has a market capitalization of $3.86 million, a P/E ratio of -0.18 and a beta of 0.19.

Avalon GloboCare (NASDAQ:ALBT) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($1.82) EPS for the quarter. The company had revenue of $0.35 million for the quarter.

About Avalon GloboCare

Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and China. The company develops and delivers transformative cellular therapeutics, precision diagnostics, and clinical laboratory services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells.